Company Expects To Be ‘One Of Two Suppliers’ Of Generic Tirosint
• By Akriti Seth
Generate a summary of this article
Listen to this article
Lannett has launched levothyroxine sodium capsules, an authorized generic version of Tirosint, in partnership with IBSA in the US. The company faces the possibility of competition, as Teva may enter the market with certain generic strengths.
Lannett expands its thyroid deficiency product portfolio with authorized Tirosint • Source: Shutterstock
Lannett Company, Inc. has announced the US launch of an authorized generic version of Tirosint (levothyroxine sodium) capsules in partnership with Institut Biochimique (IBSA).
According to the distribution deal between Lannett and IBSA, Lannett will provide sales, marketing and distribution support for the soft...
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.